Fig. 5: SARS-CoV-2 neutralizing antibodies after two doses of different combinations of COVID-19 vaccines. | Nature Communications

Fig. 5: SARS-CoV-2 neutralizing antibodies after two doses of different combinations of COVID-19 vaccines.

From: Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants

Fig. 5

a Serum samples collected 3 weeks (2D3wk) and three months (2D3mo) after the second vaccine dose from HCWs who were vaccinated with 2x BNT162b2 with a short (n = 120) or a long vaccine dose interval (n = 59), 2x mRNA-1273 (n = 67), ChAdOx1 + BNT162b2 (n = 47), or ChAdOx1+mRNA-1273 (n = 21) were compared for anti-SARS-CoV-2 S1 IgG antibodies (EIA units). The dotted line indicates the cut-off value. Neutralizing antibody responses against b D614G and c Delta variants were analysed for vaccinees with two doses of vaccine combinations: 2x BNT162b2 with a short (n = 59), or a long vaccine dose interval (n = 29), 2x mRNA-1273 (n = 25 at 2D3wk and 30 at 2D3mo), ChAdOx1 + BNT162b2 (n = 30), or ChAdOx1+mRNA-1273 (n = 18 at 2D3wk and 20 at 2D3mo). Half-maximal inhibitory dilutions (ID50) were calculated and titers <20 were marked as 10. Geometric mean titers (GMTs) for each vaccine group are shown as lines with geometric SDs. Differences in IgG antibody levels and neutralization titers between different groups were analysed with two-sided Kruskal–Wallis rank test and P-values <0.05 were considered statistically significant. P-values: <0.0001 are marked with ****, from right to left in panel a 0.0001 ***, 0.0019 **, and 0.0215 *, from right to left in panel b 0.0023 ** and ** 0.0014, and from right to left in panel c 0.0096 **, 0.0098 **, 0.0307 *, and 0.0122 *.

Back to article page